News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,256 Results
Type
Article (13711)
Company Profile (101)
Press Release (250444)
Section
Business (88020)
Career Advice (465)
Deals (15341)
Drug Delivery (66)
Drug Development (36580)
Employer Resources (49)
FDA (6282)
Job Trends (6194)
News (150163)
Policy (14022)
Tag
Academia (438)
Alliances (23205)
Alzheimer's disease (376)
Approvals (6307)
Artificial intelligence (93)
Bankruptcy (146)
Best Places to Work (4370)
Breast cancer (70)
Cancer (520)
Cardiovascular disease (54)
Career advice (406)
Cell therapy (73)
Clinical research (30762)
Collaboration (285)
Compensation (116)
COVID-19 (754)
C-suite (99)
Data (524)
Diabetes (70)
Diagnostics (1310)
Drug discovery (50)
Drug pricing (61)
Earnings (31872)
Events (37239)
Executive appointments (323)
FDA (6616)
Funding (177)
Gene therapy (90)
GLP-1 (324)
Government (1281)
Healthcare (3555)
Infectious disease (783)
Inflammatory bowel disease (54)
Interviews (59)
IPO (5870)
Job creations (2051)
Job search strategy (372)
Layoffs (175)
Legal (3427)
Lung cancer (71)
Manufacturing (127)
Medical device (1272)
Medtech (1274)
Mergers & acquisitions (9620)
Metabolic disorders (220)
Neuroscience (527)
NextGen: Class of 2025 (1585)
Non-profit (593)
Northern California (620)
Obesity (124)
Opinion (116)
Patents (91)
People (28779)
Pharmaceutical (64)
Phase I (8006)
Phase II (13013)
Phase III (11678)
Pipeline (307)
Policy (54)
Postmarket research (1401)
Preclinical (3191)
Radiopharmaceuticals (118)
Rare diseases (146)
Real estate (2632)
Regulatory (10022)
Research institute (563)
Resumes & cover letters (55)
Southern California (621)
Startups (1626)
United States (6204)
Vaccines (136)
Weight loss (89)
Date
Today (56)
Last 7 days (279)
Last 30 days (1074)
Last 365 days (12351)
2025 (2092)
2024 (12501)
2023 (14247)
2022 (19557)
2021 (20073)
2020 (19044)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10892)
Location
Africa (313)
Asia (20015)
Australia (2595)
California (1488)
Canada (811)
China (195)
Colorado (61)
Connecticut (62)
Delaware (49)
Europe (39217)
Florida (264)
Illinois (166)
Indiana (120)
Japan (76)
Kansas (53)
Maryland (225)
Massachusetts (1272)
Minnesota (82)
New Jersey (639)
New York (422)
North Carolina (352)
Northern California (620)
Pennsylvania (374)
South America (500)
Southern California (621)
Texas (196)
Virginia (62)
Washington State (101)
264,256 Results for "syros pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default
With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on its loan from Oxford Finance LLC.
November 13, 2024
·
2 min read
·
Tristan Manalac
Genetown
Syros to Participate in Upcoming May 2024 Investor Conferences
Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced that company management will participate in a fireside chat at two upcoming investor conferences.
May 7, 2024
·
1 min read
Genetown
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 02, 2024
Syros Pharmaceuticals announced the grant of a restricted stock unit award for 8,400 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros.
April 2, 2024
·
1 min read
Business
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.
May 14, 2024
·
9 min read
Business
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Syros Pharmaceuticals announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 14, 2024 to report its first quarter 2024 financial results and provide a corporate update.
May 7, 2024
·
1 min read
Genetown
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
Syros Pharmaceuticals announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome and the opportunity for tamibarotene to transform the care of newly diagnosed patients with RARA gene overexpression.
June 13, 2024
·
5 min read
Press Releases
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
October 31, 2024
·
6 min read
Genetown
Syros to Participate in TD Cowen 44th Annual Health Care Conference
Syros Pharmaceuticals today announced that its Chief Executive Officer, Conley Chee, will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference.
February 27, 2024
·
1 min read
Press Releases
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
October 24, 2024
·
1 min read
Business
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.
March 27, 2024
·
10 min read
1 of 26,426
Next
